title: [Wegener's granulomatosis in ENT: clinical presentation, diagnosis and therapy].
abstract: BACKGROUND
  Wegener's granulomatosis (WG) is a vasculitis that effects the upper and lower part of the respiratory tract and the kidneys. Untreated the disease results in death within weeks or months. The diagnosis is based on clinical criteria, level of antineutrophil cytoplasmatic antibodies (ANCA) and signs of granulomatous necrotizing vasculitis in histology.
  
  
  METHODS
  A case of an 18-year-old woman with initially symptoms of bilateral "mastoiditis" and weakness of her facial nerve is described. In this case ANCA levels remained normal for 3 months and persistent otological symptoms were predominant. The further clinical course was characterized by neurological problems (Palsy Nn. VII, IX, XII and thrombosis of the right sigmoid sinus). The initial therapy consisted of Prednisone 100 mg and Cyclophosphamide 100 mg daily. The patient has been treated successfully with Methotrexate 20 mg 1 x/week and Prednisone 15 mg/die for 4 months now.
  
  
  CONCLUSIONS
  A common clinical presentation of WG involves the upper respiratory tract. Therefore ENT-specialists should be familiar with the disease. Especially in cases of persistent signs of bilateral "Mastoiditis" and neurological symptoms WG should be ruled out as differential diagnosis. A close interdisciplinary cooperation is essential for therapy and follow-up, because systemic involvement is the limiting prognostic factor.
authors.affiliation: Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde des Universitätsklinikums Hamburg-Eppendorf, Hamburg, Germany. stesche@t-online.de
authors.forename: S
authors.initials: S
authors.lastname: Tesche
authors.forename: A
authors.initials: A
authors.lastname: Münscher
authors.forename: F U
authors.initials: FU
authors.lastname: Metternich
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008417:Mastoiditis / Q000175:diagnosis; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D010038:Otorhinolaryngologic Diseases / Q000175:diagnosis / Q000188:drug therapy; D010644:Phenprocoumon / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction; D012851:Sinus Thrombosis, Intracranial / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D010644:Phenprocoumon; D011241:Prednisone; D008727:Methotrexate